

Yung-Jue Bang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/478695/publications.pdf>

Version: 2024-02-01

612
papers

55,015
citations

3726

89
h-index

1565

217
g-index

616
all docs

616
docs citations

616
times ranked

44429
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2010, 376, 687-697.	6.3	5,899
2	Anaplastic Lymphoma Kinase Inhibition in Non- <i>Small-Cell Lung Cancer</i> . <i>New England Journal of Medicine</i> , 2010, 363, 1693-1703.	13.9	4,141
3	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 501-513.	13.9	2,216
4	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
5	Crizotinib in <i>ROS1</i> -Rearranged Non- <i>Small-Cell Lung Cancer</i> . <i>New England Journal of Medicine</i> , 2014, 371, 1963-1971.	13.9	1,656
6	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 315-321.	6.3	1,422
7	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , The, 2020, 21, 1353-1365.	5.1	1,363
8	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
9	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , The, 2012, 13, 1011-1019.	5.1	1,176
10	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
11	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
12	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	5.1	943
13	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1389-1396.	5.1	849
14	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1004-1012.	5.1	847
15	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non- <i>Small-Cell Lung Cancer Patients Treated With Gefitinib</i> . <i>Journal of Clinical Oncology</i> , 2005, 23, 2493-2501.	0.8	736
16	Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 3708-3716.	3.2	710
17	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	13.9	681
18	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	0.8	656

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	3.4	611
20	HER2-targeted therapies â€” a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 33-48.	12.5	569
21	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 309-318.	5.1	560
22	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTANâ€™A Randomized, Phase III Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2039-2049.	0.8	524
23	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2â€™Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiCâ€™A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 443-451.	0.8	490
24	HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2015, 18, 476-484.	2.7	415
25	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3935-3943.	0.8	411
26	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2011, 6, 942-946.	0.5	407
27	<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. <i>Journal of Clinical Oncology</i> , 2011, 29, 4803-4810.	0.8	404
28	Phase III, randomised trial of avelumab versus physicianâ€™s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. <i>Annals of Oncology</i> , 2018, 29, 2052-2060.	0.6	387
29	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€™Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	0.8	383
30	A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , 1993, 71, 3813-3818.	2.0	354
31	Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding. <i>Circulation</i> , 2006, 113, 51-59.	1.6	326
32	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3858-3865.	0.8	248
33	Optimization of Patient Selection for Gefitinib in Nonâ€™Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 2538-2544.	3.2	245
34	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 620.	3.4	233
35	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1637-1651.	5.1	233
36	Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. <i>Laboratory Investigation</i> , 2004, 84, 479-484.	1.7	199

#	ARTICLE	IF	CITATIONS
37	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	2.2	187
38	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€“High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	3.4	184
39	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015, 10, e0139749.	1.1	183
40	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	0.8	183
41	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
42	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 1449-1458.	1.2	179
43	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	3.2	179
44	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIIE extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005, 106, 3785-3790.	0.6	165
45	The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor \pm -negative breast cancer cells to tamoxifen. <i>Oncogene</i> , 2004, 23, 1724-1736.	2.6	152
46	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa [®] , ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005, 113, 109-115.	2.3	152
47	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1474-1480.	0.5	148
48	Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation. <i>Clinical Cancer Research</i> , 2004, 10, 5271-5281.	3.2	139
49	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33.	2.2	138
50	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
51	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	0.8	134
52	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
53	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019, 15, 943-952.	1.1	133
54	Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 52-63.	1.0	131

#	ARTICLE	IF	CITATIONS
55	Transcriptional repression of the transforming growth factor- β type I receptor gene by DNA methylation results in the development of TGF- β resistance in human gastric cancer. <i>Oncogene</i> , 1999, 18, 7280-7286.	2.6	130
56	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€‘05): a single-arm, phase 1bâ€‘2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	5.1	130
57	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer â€‘ Differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 2941-2953.	1.3	129
58	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007, 7, 203.	1.1	126
59	Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. <i>Human Gene Therapy</i> , 2001, 12, 671-684.	1.4	123
60	Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. <i>Oncogene</i> , 2004, 23, 1333-1341.	2.6	122
61	Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. <i>Histopathology</i> , 2011, 59, 822-831.	1.6	122
62	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
63	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5671-5678.	3.2	121
64	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4007-LBA4007.	0.8	119
65	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009, 65, 80-84.	0.9	118
66	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	1.1	117
67	<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. <i>Molecular Carcinogenesis</i> , 2010, 49, 353-362.	1.3	116
68	RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 865-877.	1.9	116
69	DLCâ€‘1 suppresses nonâ€‘small cell lung cancer growth and invasion by RhoGAPâ€‘dependent and independent mechanisms. <i>Molecular Carcinogenesis</i> , 2008, 47, 326-337.	1.3	115
70	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502.	0.8	114
71	Establishment and characterization of human gastric carcinoma cell lines. , 1997, 70, 443-449.		111
72	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008, 272, 296-306.	3.2	111

#	ARTICLE	IF	CITATIONS
73	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. <i>BMC Cancer</i> , 2008, 8, 307.	1.1	108
74	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 566-577.	1.9	108
75	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	3.2	107
76	Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. <i>Oncogene</i> , 2003, 22, 3943-3951.	2.6	104
77	Docetaxel 75 mg/m ² is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 248-254.	0.6	103
78	Hepatitis B Virus Infection and B-Cell Non-Hodgkin's Lymphoma in a Hepatitis B Endemic Area: A Case-control Study. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 471-477.	1.7	102
79	Increased MAPK Activity and MKP-1 Overexpression in Human Gastric Adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1998, 250, 43-47.	1.0	100
80	A Novel ets-related Transcription Factor, ERT/ESX/ESE-1, Regulates Expression of the Transforming Growth Factor- β Type II Receptor. <i>Journal of Biological Chemistry</i> , 1998, 273, 110-117.	1.6	100
81	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. <i>Cancer Letters</i> , 2013, 335, 145-152.	3.2	100
82	Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3085-3095.	1.9	99
83	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2567.	0.8	98
84	Involvement of NF- κ B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. <i>Carcinogenesis</i> , 2009, 30, 753-757.	1.3	97
85	Aggressiveness of Cancer-Care near the End-of-Life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 381-386.	0.6	94
86	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
87	Identification and Characterization of a Novel Cancer/Testis Antigen Gene CAGE. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 715-726.	1.0	93
88	In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. <i>Peptides</i> , 2003, 24, 945-953.	1.2	93
89	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
90	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615.	1.3	93

#	ARTICLE	IF	CITATIONS
91	Cyclooxygenase-2 Inhibits Novel Ginseng Metabolite-Mediated Apoptosis. <i>Cancer Research</i> , 2005, 65, 1952-1960.	0.4	91
92	Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2. <i>PLoS ONE</i> , 2009, 4, e5933.	1.1	91
93	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
94	AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. <i>Oncogene</i> , 2004, 23, 7095-7103.	2.6	89
95	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	0.9	89
96	Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 318-322.	1.0	89
97	Epigenetic-Based Therapies in Cancer. <i>Drugs</i> , 2011, 71, 2391-2403.	4.9	88
98	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	1.3	86
99	Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. <i>Cancer</i> , 2012, 118, 6162-6170.	2.0	83
100	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012, 77, 460-463.	0.9	82
101	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009, 9, 73.	1.1	81
102	Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2017, 3, 767.	3.4	80
103	Transforming Growth Factor- β 1 Induces Apoptosis through Fas Ligand-independent Activation of the Fas Death Pathway in Human Gastric SNU-620 Carcinoma Cells. <i>Molecular Biology of the Cell</i> , 2004, 15, 420-434.	0.9	79
104	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011, 12, 9-46.	1.5	79
105	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407.	0.9	78
106	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
107	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	3.4	78
108	Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF- κ B as a possible target. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 551-60.	1.2	77

#	ARTICLE	IF	CITATIONS
109	Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. <i>Cancer</i> , 2004, 100, 1961-1966.	2.0	76
110	Comparison of Intrathecal Chemotherapy for Leptomeningeal Carcinomatosis of a Solid Tumor: Methotrexate Alone Versus Methotrexate in Combination with Cytosine Arabinoside and Hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 608-612.	0.6	75
111	Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin. <i>Carcinogenesis</i> , 2004, 26, 359-367.	1.3	75
112	Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma. <i>Acta Oncologica</i> , 2003, 42, 779-783.	0.8	74
113	DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 72-77.	1.0	74
114	Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 637-648.	1.1	74
115	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA4001-LBA4001.	0.8	74
116	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2044-2046.	0.5	73
117	The potential for crizotinib in non-small cell lung cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 279-291.	1.4	72
118	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
119	METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4012-4012.	0.8	72
120	Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. <i>Clinical Cancer Research</i> , 2003, 9, 433-40.	3.2	72
121	Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e64271.	1.1	71
122	Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. <i>Cancer</i> , 2004, 101, 2257-2260.	2.0	70
123	Loss of TGF- β signaling contributes to autoimmune pancreatitis. <i>Journal of Clinical Investigation</i> , 2000, 105, 1057-1065.	3.9	70
124	Cdk2-dependent Phosphorylation of the NF-Y Transcription Factor and Its Involvement in the p53-p21 Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2003, 278, 36966-36972.	1.6	69
125	The Endogenous Ratio of Smad2 and Smad3 Influences the Cytostatic Function of Smad3. <i>Molecular Biology of the Cell</i> , 2005, 16, 4672-4683.	0.9	68
126	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	3.2	67

#	ARTICLE	IF	CITATIONS
127	Enzastaurin, a Protein Kinase C β Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells. <i>Cancer Research</i> , 2008, 68, 1916-1926.	0.4	66
128	Inhibition of Histone Deacetylase 10 Induces Thioredoxin-Interacting Protein and Causes Accumulation of Reactive Oxygen Species in SNU-620 Human Gastric Cancer Cells. <i>Molecules and Cells</i> , 2010, 30, 107-112.	1.0	66
129	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. <i>Journal of Thoracic Oncology</i> , 2011, 6, 905-912.	0.5	66
130	Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. , 1997, 80, 1889-1896.		65
131	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. <i>Supportive Care in Cancer</i> , 2006, 14, 103-108.	1.0	65
132	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2526-2536.	1.9	65
133	Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1445-1450.	0.5	65
134	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7508-7508.	0.8	65
135	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008, 8, 148.	1.1	64
136	Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1045-1055.	1.1	64
137	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	1.4	64
138	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474.	1.7	64
139	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2018, 50, 835-842.	1.3	64
140	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007, 7, 63.	1.1	63
141	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015, 121, 2612-2617.	2.0	63
142	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	0.8	63
143	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 439-451.	1.9	62
144	Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. <i>Cancer Letters</i> , 2002, 184, 197-206.	3.2	61

#	ARTICLE	IF	CITATIONS
145	Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions. <i>Oncogene</i> , 2004, 23, 4084-4088.	2.6	61
146	Oocyte-based screening of cytokinesis inhibitors and identification of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors. <i>Oncogene</i> , 2005, 24, 4813-4819.	2.6	61
147	Histone Deacetylase Inhibitors for Cancer Therapy. <i>Epigenetics</i> , 2006, 1, 15-24.	1.3	61
148	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2011, 11, 452.	1.1	61
149	Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. <i>BMC Gastroenterology</i> , 2011, 11, 56.	0.8	60
150	Identification and characterization of a novel cancer/testis antigen gene CAGE-1. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2003, 1625, 173-182.	2.4	59
151	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529.	3.2	59
152	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients. <i>Cancer</i> , 2003, 98, 2651-2656.	2.0	58
153	Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 92, 927-935.	0.6	58
154	Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. <i>Journal of Molecular Medicine</i> , 2007, 85, 1137-1148.	1.7	58
155	Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 593-599.	0.6	58
156	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3-3.	0.8	58
157	Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 16-26.	1.9	57
158	CD99 Regulates the Transport of MHC Class I Molecules from the Golgi Complex to the Cell Surface. <i>Journal of Immunology</i> , 2001, 166, 787-794.	0.4	56
159	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016, 48, 171-179.	1.3	56
160	Methylation of specific CpG sites in the promoter region could significantly down-regulate p16INK4a expression in gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2000, 87, 236-240.	2.3	55
161	Role of Adjuvant Chemoradiotherapy for Ampulla of Vater Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 436-441.	0.4	55
162	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	0.8	55

#	ARTICLE	IF	CITATIONS
163	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4012-4012.	0.8	55
164	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1274-1282.	0.6	54
165	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	0.7	54
166	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	0.5	54
167	Effects of Structure of Rho GTPase-activating Protein DLC-1 on Cell Morphology and Migration. <i>Journal of Biological Chemistry</i> , 2008, 283, 32762-32770.	1.6	53
168	Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. <i>Abdominal Imaging</i> , 2009, 34, 430-440.	2.0	53
169	Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. <i>Cancer</i> , 2010, 116, 2890-2901.	2.0	53
170	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	3.2	53
171	Bcl-xL and E1B-19K Proteins Inhibit p53-induced Irreversible Growth Arrest and Senescence by Preventing Reactive Oxygen Species-dependent p38 Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 17765-17771.	1.6	52
172	Randomized Controlled Trial Comparing Gastrectomy Plus Chemotherapy with Chemotherapy Alone in Advanced Gastric Cancer with A Single Non-curable Factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 504-506.	0.6	52
173	Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). <i>European Radiology</i> , 2013, 23, 1352-1360.	2.3	52
174	Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients. <i>Pathobiology</i> , 2013, 80, 127-137.	1.9	52
175	KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX. <i>Annals of Surgical Oncology</i> , 2015, 22, 187-194.	0.7	52
176	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018, 430, 123-132.	3.2	52
177	Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-β1-induced apoptosis in human gastric cancer cells. <i>Oncogene</i> , 2001, 20, 1254-1265.	2.6	51
178	Aberrant methylation of integrin β4 gene in human gastric cancer cells. <i>Oncogene</i> , 2004, 23, 3474-3480.	2.6	51
179	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 374.	1.1	51
180	CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16868-16873.	3.3	51

#	ARTICLE	IF	CITATIONS
181	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262.	2.7	51
182	Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. <i>International Journal of Oncology</i> , 2008, 32, 89-95.	1.4	51
183	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 607-615.	1.9	50
184	Quality of Life in the Trastuzumab for Gastric Cancer Trial. <i>Oncologist</i> , 2014, 19, 712-719.	1.9	50
185	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341.	0.8	50
186	Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. , 1999, 86, 559-565.		49
187	Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5745-5751.	2.9	49
188	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 3579-3586.	2.0	49
189	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. <i>International Journal of Cancer</i> , 2013, 132, 2209-2216.	2.3	49
190	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	1.3	49
191	Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines. <i>International Journal of Cancer</i> , 2000, 86, 632-635.	2.3	48
192	Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. <i>BMC Cancer</i> , 2010, 10, 557.	1.1	48
193	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	0.9	48
194	Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. <i>International Journal of Cancer</i> , 2017, 140, 109-119.	2.3	48
195	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	1.7	48
196	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011, 302, 155-165.	3.2	47
197	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	0.8	47
198	High ratio of programmed cell death protein 1 (PD-1)+/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 165-170.	0.3	47

#	ARTICLE	IF	CITATIONS
199	Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. <i>Cancer Science</i> , 2011, 102, 1388-1395.	1.7	46
200	Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1740-1751.	5.1	46
201	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 238-243.	0.6	45
202	Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. <i>Journal of Molecular Medicine</i> , 2008, 86, 117-128.	1.7	45
203	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. <i>Targeted Oncology</i> , 2016, 11, 815-824.	1.7	45
204	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1145-1154.	1.9	45
205	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
206	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171.	2.9	43
207	The Signaling Network of Transforming Growth Factor β 1, Protein Kinase C γ , and Integrin Underlies the Spreading and Invasiveness of Gastric Carcinoma Cells. <i>Molecular and Cellular Biology</i> , 2005, 25, 6921-6936.	1.1	42
208	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , 2010, 10, 448.	1.1	42
209	RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. <i>Cancer Letters</i> , 2010, 299, 22-28.	3.2	42
210	Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. <i>International Journal of Cancer</i> , 2014, 134, 72-80.	2.3	42
211	Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8032-8032.	0.8	42
212	Genetic integrity of transforming growth factor β 2 (TGF- β 2) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF- β 2. , 1998, 77, 620-625.		41
213	Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 75-80.	0.4	41
214	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 153-160.	1.1	41
215	Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 112-118.	0.6	41
216	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9067-9067.	0.8	41

#	ARTICLE	IF	CITATIONS
217	Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody. <i>PLoS ONE</i> , 2012, 7, e33322.	1.1	41
218	Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. <i>BMC Cancer</i> , 2009, 9, 345.	1.1	40
219	NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. <i>International Journal of Oncology</i> , 2012, 40, 1259-1266.	1.4	40
220	Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 237-245.	0.7	40
221	Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016, 19, 1066-1079.	2.7	40
222	Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. <i>Journal of Surgical Oncology</i> , 2013, 107, 511-516.	0.8	39
223	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	5.1	39
224	A Case of Glomeruloid Hemangioma Associated With Multicentric Castleman's Disease. <i>American Journal of Dermatopathology</i> , 1998, 20, 266-270.	0.3	39
225	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2 ⁺ advanced gastric or gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 278-278.	0.8	39
226	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non-Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 4232-4236.	3.2	38
227	Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 800-805.	1.4	38
228	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 228-238.	1.9	38
229	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 843-851.	1.1	37
230	Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 947-956.	0.2	37
231	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 140-140.	0.8	37
232	Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 318-323.	1.0	36
233	Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. <i>Laboratory Investigation</i> , 2008, 88, 153-160.	1.7	36
234	Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. <i>International Journal of Oncology</i> , 0, , .	1.4	36

#	ARTICLE	IF	CITATIONS
235	A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. <i>BMC Cancer</i> , 2014, 14, 795.	1.1	36
236	Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA3-LBA3.	0.8	36
237	Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2535-2535.	0.8	36
238	A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4014-4014.	0.8	36
239	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3014-3014.	0.8	36
240	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006, 54, 201-207.	0.9	35
241	Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 136-140.	0.6	35
242	A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 560-560.	0.8	35
243	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	3.2	35
244	Truncation of the TGF- β 2 type II receptor gene results in insensitivity to TGF- β 2 in human gastric cancer cells. <i>Oncogene</i> , 1999, 18, 2213-2219.	2.6	34
245	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. <i>Cancer</i> , 2000, 89, 2521-2526.	2.0	34
246	Public Awareness of Gastric Cancer Risk Factors and Disease Screening in a High Risk Region: A Population-Based Study. <i>Cancer Research and Treatment</i> , 2009, 41, 59.	1.3	34
247	Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1323-1331.	1.1	34
248	Population Pharmacokinetics of Pegylated Liposomal CKD602 (Sâ€CKD602) in Patients With Advanced Malignancies. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 180-194.	1.0	34
249	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. <i>Laboratory Investigation</i> , 2012, 92, 1033-1044.	1.7	34
250	Findings of a 1303 Korean whole-exome sequencing study. <i>Experimental and Molecular Medicine</i> , 2017, 49, e356-e356.	3.2	34
251	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GE) cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4011-4011.	0.8	34
252	A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 527-536.	1.1	33

#	ARTICLE	IF	CITATIONS
253	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 1095-1103.	2.7	33
254	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 2847-2855.	1.1	33
255	A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. <i>Oncology Reports</i> , 2004, 12, 1059-64.	1.2	33
256	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	1.2	32
257	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. <i>European Journal of Cancer</i> , 2019, 108, 17-24.	1.3	32
258	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020, 111, 513-527.	1.7	32
259	Cell Adhesion Status-dependent Histone Acetylation Is Regulated through Intracellular Contractility-related Signaling Activities. <i>Journal of Biological Chemistry</i> , 2005, 280, 28357-28364.	1.6	31
260	Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 589-595.	0.6	31
261	Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 94-100.	2.1	31
262	Treatment of ALK-Positive Non-Small Cell Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1201-1204.	1.2	31
263	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	2.7	31
264	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2520-2520.	0.8	31
265	Cytotoxic effects of pemetrexed in gastric cancer cells. <i>Cancer Science</i> , 2005, 96, 365-371.	1.7	29
266	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 344-350.	0.6	29
267	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009, 65, 204-207.	0.9	29
268	Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1537-1542.	1.4	29
269	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. <i>Acta Oncologica</i> , 2012, 51, 528-536.	0.8	29
270	Safety and Antitumor Activity of Î±-PD-L1 Antibody as Monotherapy or in Combination with Î±-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29

#	ARTICLE	IF	CITATIONS
271	TGF- β 1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27Kip1 CDK inhibitor in hepatoma cells replated on fibronectin. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1743, 151-161.	1.9	28
272	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 497-507.	1.1	28
273	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	1.0	28
274	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. <i>Gastric Cancer</i> , 2013, 16, 581-589.	2.7	28
275	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1206-1214.	2.7	28
276	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 149-166.	1.3	28
277	The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. <i>Anticancer Research</i> , 2012, 32, 1547-53.	0.5	28
278	Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 99-101.	0.9	27
279	TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity. <i>Biochemical Journal</i> , 2004, 379, 141-150.	1.7	27
280	Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G126-G132.	1.6	27
281	Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4013-4013.	0.8	27
282	VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 518-526.	1.3	27
283	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. <i>Cancer</i> , 1999, 86, 1109-1115.	2.0	26
284	Attenuation of Transforming Growth Factor β 2-Induced Growth Inhibition in Human Hepatocellular Carcinoma Cell Lines by Cyclin D1 Overexpression. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 383-389.	1.0	26
285	Chylothorax in Gorham's Disease. <i>Journal of Korean Medical Science</i> , 2002, 17, 826.	1.1	26
286	Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 2003, 310, 844-851.	1.0	26
287	A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor. <i>Oncology</i> , 2009, 76, 326-332.	0.9	26
288	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017, 8, 79441-79452.	0.8	26

#	ARTICLE	IF	CITATIONS
289	Metastasis-Associated Protein S100A4 and p53 Predict Relapse in Curatively Resected Stage III and IV (M0) Gastric Cancer. <i>Cancer Investigation</i> , 2008, 26, 152-158.	0.6	25
290	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) <i>Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50</i>	0.6	25
291	Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, S115.	1.1	24
292	Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. <i>Cancer Science</i> , 2010, 101, 793-799.	1.7	24
293	Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39943.	1.1	24
294	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. <i>BMC Cancer</i> , 2017, 17, 646.	1.1	24
295	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β 2 and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3202-3210.	3.2	24
296	Transforming Growth Factor- β 2 Induces Apoptosis in Activated Murine T Cells through the Activation of Caspase 1-like Protease. <i>Cellular Immunology</i> , 2000, 204, 46-54.	1.4	23
297	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 400-404.	0.6	23
298	ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy. <i>Oncology</i> , 2012, 83, 218-227.	0.9	23
299	Long-term trastuzumab (Herceptin $\hat{\text{A}}$) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. <i>BMC Cancer</i> , 2018, 18, 295.	1.1	23
300	A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11-11.	0.8	23
301	Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution. <i>Cancer Research and Treatment</i> , 2017, 49, 473-483.	1.3	23
302	Role of Adjuvant Chemoradiotherapy for Duodenal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 533-536.	0.6	22
303	Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 381-389.	1.1	22
304	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. <i>Journal of Korean Medical Science</i> , 2014, 29, 1094.	1.1	22
305	Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5581-5581.	0.8	22
306	KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS185-TPS185.	0.8	22

#	ARTICLE	IF	CITATIONS
307	Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1167-1179.	1.3	22
308	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 901-905.	0.4	21
309	High serum TGF- β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 107-114.	1.1	21
310	Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer. <i>Oncology</i> , 2012, 83, 57-66.	0.9	21
311	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012, 23, 288-297.	0.7	21
312	Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. <i>Investigational New Drugs</i> , 2013, 31, 1547-1558.	1.2	21
313	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>c-MET</i> -amplified gastric cancer. <i>Oncotarget</i> , 2017, 8, 79546-79555.	0.8	21
314	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	1.9	21
315	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11131.	1.6	21
316	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	3.2	21
317	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	3.2	21
318	Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy. <i>Journal of Korean Medical Science</i> , 2009, 24, 910.	1.1	20
319	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017, 58, 899-904.	2.8	20
320	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	1.7	20
321	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
322	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2514-2514.	0.8	20
323	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GE) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. <i>Journal of Clinical Oncology</i> , 2018, 36, 92-92.	0.8	20
324	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GE) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	0.8	20

#	ARTICLE	IF	CITATIONS
325	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36.	1.3	20
326	Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 109, 359-363.	0.6	19
327	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. <i>Investigational New Drugs</i> , 2012, 30, 1164-1174.	1.2	19
328	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015, 15, 721.	1.1	19
329	Korean Cancer Patients's Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	1.3	19
330	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. <i>British Journal of Cancer</i> , 2019, 121, 332-339.	2.9	19
331	Alteration of Signal-Transducing Molecules and Phenotypical Characteristics in Peripheral Blood Lymphocytes from Gastric Carcinoma Patients. <i>Pathobiology</i> , 1999, 67, 123-128.	1.9	19
332	The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4010-4010.	0.8	19
333	Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 578-587.	1.3	19
334	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007, 15, 631-636.	1.0	18
335	Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. <i>Annals of Hematology</i> , 2009, 88, 829-838.	0.8	18
336	Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1404-1412.	1.2	18
337	Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1234-1243.	0.7	18
338	Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis. <i>Cancer Research and Treatment</i> , 2017, 49, 643-655.	1.3	18
339	Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer. <i>Journal of Korean Medical Science</i> , 2005, 20, 806.	1.1	17
340	Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 720-726.	0.6	17
341	Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2009, 14, 540-547.	1.9	17
342	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2010, 21, 777-784.	0.7	17

#	ARTICLE	IF	CITATIONS
343	Adjuvant and Neoadjuvant Therapy for Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 311-320.	1.3	17
344	Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2013, 20, 167-173.	1.3	17
345	Registry of gastric cancer treatment evaluation (<sc>REGATE</sc>): <sc>I</sc> baseline disease characteristics. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 38-52.	0.7	17
346	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 13-25.	0.6	17
347	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015, 7, 63.	1.8	17
348	Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. <i>Oncologist</i> , 2015, 20, 896-897.	1.9	17
349	Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. <i>Targeted Oncology</i> , 2017, 12, 211-218.	1.7	17
350	Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 33-39.	2.8	17
351	The influence of treatment response on the impact of resection margin status after preoperative chemoradiotherapy in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 505-505.	0.8	17
352	A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. <i>Cancer Research and Treatment</i> , 2014, 46, 234-242.	1.3	17
353	Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. <i>Anticancer Research</i> , 2006, 26, 3429-38.	0.5	17
354	A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. <i>Cancer</i> , 2001, 91, 1549-1556.	2.0	16
355	Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3004-3004.	0.8	16
356	Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3026-3026.	0.8	16
357	Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 380-385.	0.6	15
358	Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. <i>Experimental and Molecular Medicine</i> , 2008, 40, 639.	3.2	15
359	DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. <i>International Journal of Oncology</i> , 2010, 36, 1563-72.	1.4	15
360	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012, 30, 2148-2160.	1.2	15

#	ARTICLE	IF	CITATIONS
361	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. <i>Journal of Breast Cancer</i> , 2012, 15, 427.	0.8	15
362	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1435-1443.	1.1	15
363	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015, 20, 926-933.	1.9	15
364	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5771-5780.	3.2	15
365	Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5-5.	0.8	15
366	Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4043-4043.	0.8	15
367	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 65-65.	0.8	15
368	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016, 11, e0151406.	1.1	15
369	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016, 48, 990-997.	1.3	15
370	Analysis of spinal cord proteome in the rats with mechanical allodynia after the spinal nerve injury. <i>Biotechnology Letters</i> , 2003, 25, 2071-2078.	1.1	14
371	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 2516-2522.	2.0	14
372	Prognostic Factors Affecting the Outcome of Salvage Radiotherapy for Isolated Locoregional Recurrence After Mastectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 23-27.	0.6	14
373	P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. <i>Human Pathology</i> , 2010, 41, 877-885.	1.1	14
374	Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 391-395.	1.2	14
375	The prognostic role of soluble TGF β and its dynamics in unresectable pancreatic cancer treated with chemotherapy. <i>Cancer Medicine</i> , 2020, 9, 43-51.	1.3	14
376	A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2586-2586.	0.8	14
377	More Accurate Prediction of Metastatic Pancreatic Cancer Patients's Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016, 11, e0145692.	1.1	14
378	Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 945-956.	1.3	14

#	ARTICLE	IF	CITATIONS
379	Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF- κ B activity in lung cancer cells. <i>Lung Cancer</i> , 2005, 48, 201-209.	0.9	13
380	A-kinase anchoring protein 12 regulates the completion of cytokinesis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 85-89.	1.0	13
381	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	2.7	13
382	Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. <i>Targeted Oncology</i> , 2020, 15, 75-84.	1.7	13
383	MetGastric: A randomized phase III study of onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4155-TPS4155.	0.8	13
384	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1 \geq 10% positive (CPS \geq 10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 427-427.	0.8	13
385	CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 1438.	1.4	13
386	TGF- β 2 Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. <i>Cancer Research and Treatment</i> , 1970, 47, 101-109.	1.3	13
387	Locoregional Response and Increased Natural Killer Activity after Intratumoral Injection of HLA-B7/12-Microglobulin Gene in Patients with Cancer. <i>Human Gene Therapy</i> , 1998, 9, 2031-2038.	1.4	12
388	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 821-836.	1.5	12
389	Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 263-270.	1.1	12
390	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. <i>Cancer Letters</i> , 2012, 321, 128-136.	3.2	12
391	The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer. <i>BMC Cancer</i> , 2013, 13, 576.	1.1	12
392	Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1567-1574.	1.2	12
393	A phase I study of the human anti-activin receptor-like kinase 1 antibody PF 03446962 in Asian patients with advanced solid tumors. <i>Cancer Medicine</i> , 2016, 5, 1454-1463.	1.3	12
394	Pertuzumab in gastrointestinal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 243-253.	1.4	12
395	Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. <i>Hpb</i> , 2017, 19, 421-428.	0.1	12
396	S-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 30-39.	1.3	12

#	ARTICLE	IF	CITATIONS
397	GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 932-940.	2.7	12
398	Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4124-4124.	0.8	12
399	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS195-TPS195.	0.8	12
400	A multi-center, late phase II clinical trial of Genexol [®] (paclitaxel) and cisplatin for patients with advanced gastric cancer. <i>Oncology Reports</i> , 0, , .	1.2	12
401	Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. <i>Cancer Research and Treatment</i> , 2019, 51, 451-463.	1.3	12
402	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1178-1187.	1.3	12
403	p130 Mediates TGF- β ² -Induced Cell-Cycle Arrest in Rb Mutant HT-3 Cells. <i>Gynecologic Oncology</i> , 2002, 86, 184-189.	0.6	11
404	Capecitabine in gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1791-1806.	1.1	11
405	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	2.7	11
406	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172307.	1.1	11
407	Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4118-4118.	0.8	11
408	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€™Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	0.8	11
409	Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4037-4037.	0.8	11
410	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4031-4031.	0.8	11
411	Prognostic Factors of Patients With Thymoma. <i>Korean Journal of Internal Medicine</i> , 1996, 11, 40-49.	0.7	11
412	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 687-696.	1.3	11
413	Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. <i>Cancer Research and Treatment</i> , 2019, 51, 832-840.	1.3	11
414	A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells. <i>International Journal of Oncology</i> , 2003, 23, 1087.	1.4	10

#	ARTICLE	IF	CITATIONS
415	DNA methyltransferase 3B mutant in ICF syndrome interacts non-covalently with SUMO-1. <i>Journal of Molecular Medicine</i> , 2008, 86, 1269-1277.	1.7	10
416	DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2462-2471.	1.2	10
417	Registry of gastric cancer treatment evaluation (<scp>REGATE</scp>): <scp>II</scp> treatment practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 373-380.	0.7	10
418	Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 253-266.	1.1	10
419	Capecitabine for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1471-1481.	1.4	10
420	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524.	1.9	10
421	Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017, 411, 162-170.	3.2	10
422	KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. <i>Annals of Oncology</i> , 2017, 28, iii153.	0.6	10
423	Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 125-129.	0.6	10
424	A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.. <i>Journal of Clinical Oncology</i> , 2012, 30, 54-54.	0.8	10
425	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2517-2517.	0.8	10
426	Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS183-TPS183.	0.8	10
427	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4067-4067.	0.8	10
428	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4062-4062.	0.8	10
429	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055.	1.3	10
430	Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2010, 25, 684.	1.1	9
431	Age <40–Years is an Independent Prognostic Factor Predicting Inferior Overall Survival in Patients Treated with Breast Conservative Therapy. <i>Breast Journal</i> , 2011, 17, 75-78.	0.4	9
432	Nomogram Prediction of Survival and Recurrence in Patients With Extrahepatic Bile Duct Cancer Undergoing Curative Resection Followed by Adjuvant Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 499-504.	0.4	9

#	ARTICLE	IF	CITATIONS
433	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 690.	1.1	9
434	Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 1069-1075.	1.0	9
435	Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance., 2014, , .		9
436	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4136-TPS4136.	0.8	9
437	KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4136-TPS4136.	0.8	9
438	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103.	1.3	9
439	The first documentation of Li-Fraumeni syndrome in Korea. <i>Journal of Korean Medical Science</i> , 1995, 10, 205.	1.1	8
440	Is Duodenal Invasion a Relevant Prognosticator in Patients Undergoing Adjuvant Chemoradiotherapy for Distal Common Bile Duct Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1186-1190.	0.4	8
441	Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy. <i>Journal of Korean Medical Science</i> , 2010, 25, 235.	1.1	8
442	Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. <i>BMC Cancer</i> , 2011, 11, 188.	1.1	8
443	The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1020-1027.	0.6	8
444	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. <i>Cancer Letters</i> , 2012, 316, 77-84.	3.2	8
445	Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. <i>International Journal of Nanomedicine</i> , 2012, 7, 5555.	3.3	8
446	Effect of lapatinib on oral digoxin absorption in patients. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 449-453.	0.8	8
447	Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer. <i>Oncology Letters</i> , 2019, 17, 4383-4392.	0.8	8
448	The Synergism between Belotecan and Cisplatin in G astric Cancer. <i>Cancer Research and Treatment</i> , 2006, 38, 159.	1.3	8
449	Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS458-TPS458.	0.8	8
450	Rapidly developing T-cell posttransplantation lymphoproliferative disorder. <i>American Journal of Kidney Diseases</i> , 1999, 34, e3.1-e3.5.	2.1	7

#	ARTICLE	IF	CITATIONS
451	Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial. Japanese Journal of Clinical Oncology, 2007, 37, 501-508.	0.6	7
452	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 427-432.	0.9	7
453	Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemotherapy and Pharmacology, 2011, 68, 165-175.	1.1	7
454	Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes. Cellular Oncology (Dordrecht), 2011, 34, 45-54.	2.1	7
455	Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome: the 10-year experience of a single center. Hematology, 2011, 16, 73-79.	0.7	7
456	Distant Metastasis Risk Stratification for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiation for Extrahepatic Bile Duct Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 81-87.	0.4	7
457	Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer. Journal of Nuclear Medicine, 2017, 58, 1255-1261.	2.8	7
458	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer, 2021, 24, 1330-1340.	2.7	7
459	Abstract 4017: Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. Cancer Research, 2012, 72, 4017-4017.	0.4	7
460	Randomized controlled trial of comparing gastrectomy (Gx) plus chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a single non-curable factor: JCOG 0705/KGCA01 study (REGATTA).. Journal of Clinical Oncology, 2015, 33, 200-200.	0.8	7
461	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. Journal of Clinical Oncology, 2015, 33, 9-9.	0.8	7
462	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.. Journal of Clinical Oncology, 2018, 36, 100-100.	0.8	7
463	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. Journal of Clinical Oncology, 2020, 38, 4513-4513.	0.8	7
464	Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. Radiation Oncology Journal, 2012, 30, 213.	0.7	7
465	TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. Cancer Research and Treatment, 2018, 50, 398-404.	1.3	7
466	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80.	0.5	7
467	Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis - malonato[(4 R , 5 R)-4,5-bis(aminomethyl)- 2-isopropyl-1,3-dioxolane]platinum(II). Cancer Chemotherapy and Pharmacology, 1997, 41, 109-116.	1.1	6
468	Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 6-12.	0.6	6

#	ARTICLE	IF	CITATIONS
469	Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome. <i>Journal of Korean Medical Science</i> , 2006, 21, 633.	1.1	6
470	Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2534-2543.	1.2	6
471	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (IFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1017-1026.	1.1	6
472	Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines. <i>International Journal of Oncology</i> , 2013, 43, 2073-2081.	1.4	6
473	The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1833-1841.	0.9	6
474	CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. <i>Cancer Research and Treatment</i> , 2017, 49, 807-815.	1.3	6
475	TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. <i>Cancers</i> , 2020, 12, 334.	1.7	6
476	ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E-mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2604-TPS2604.	0.8	6
477	Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4135-TPS4135.	0.8	6
478	Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer. <i>Cancer Research and Treatment</i> , 2008, 40, 81.	1.3	6
479	Dose-exposure-response relationship between AZD6738 and peripheral monocytes.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14063-e14063.	0.8	6
480	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4540-4540.	0.8	6
481	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3376-88.	1.4	6
482	Ramosetron for the Prevention of Nausea and Vomiting During 5-Fluorouracil-Based Chemoradiotherapy for Pancreatico-biliary Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 111-115.	0.6	5
483	Trastuzumab for gastric cancer treatment – Authors' reply. <i>Lancet</i> , The, 2010, 376, 1735-1736.	6.3	5
484	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 245-252.	0.6	5
485	Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2016, 19, 394.	0.8	5
486	Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 346-349.	0.6	5

#	ARTICLE	IF	CITATIONS
487	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	2.0	5
488	Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4148-TPS4148.	0.8	5
489	Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2502-2502.	0.8	5
490	Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , 2016, 34, 161-161.	0.8	5
491	Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. <i>Journal of Clinical Oncology</i> , 2016, 34, 309-309.	0.8	5
492	Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. <i>Tumori</i> , 2011, 97, 280-5.	0.6	5
493	A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2003, 35, 30-34.	1.3	5
494	Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2015, 47, 274-281.	1.3	5
495	Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 886-900.	1.3	5
496	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 712-712.	0.8	5
497	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2â€“positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2022, 40, 242-242.	0.8	5
498	Smad2 mediates Erk1/2 activation by TGF-beta1 in suspended, but not in adherent, gastric carcinoma cells. <i>International Journal of Oncology</i> , 2004, 24, 1229-34.	1.4	5
499	A case of leukemia-associated arthritis: identification of leukemic cells in synovial fluid by light microscopy. <i>Journal of Korean Medical Science</i> , 1987, 2, 255.	1.1	4
500	Negative Impact of Heat Exposure on Cosmesis after Conservative Treatment for Breast Cancer. <i>Tumori</i> , 2007, 93, 591-596.	0.6	4
501	Does Adjuvant Radiotherapy Suppress Liver Regeneration After Partial Hepatectomy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 67-72.	0.4	4
502	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
503	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 447-455.	1.1	4
504	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019, 24, 1037-e636.	1.9	4

#	ARTICLE	IF	CITATIONS
505	Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.. Journal of Clinical Oncology, 2016, 34, TPS4137-TPS4137.	0.8	4
506	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. Journal of Clinical Oncology, 2020, 38, TPS463-TPS463.	0.8	4
507	498â€¦Evorpaccept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01. , 2021, 9, A530-A530.		4
508	Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncology Reports, 2005, 14, 481.	1.2	3
509	The Sequencing of Chemotherapy and Radiotherapy in Breast Cancer Patients after Mastectomy. Tumori, 2010, 96, 28-33.	0.6	3
510	Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors. , 2015, , .		3
511	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157.	0.8	3
512	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4147-TPS4147.	0.8	3
513	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 523-523.	0.8	3
514	Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2016, 34, 4041-4041.	0.8	3
515	The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4144-TPS4144.	0.8	3
516	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2016, 34, 64-64.	0.8	3
517	Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.. Journal of Clinical Oncology, 2016, 34, TPS184-TPS184.	0.8	3
518	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4021-4021.	0.8	3
519	A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.. Journal of Clinical Oncology, 2018, 36, TPS4133-TPS4133.	0.8	3
520	A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.. Journal of Clinical Oncology, 2019, 37, TPS180-TPS180.	0.8	3
521	Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. Oncotarget, 2017, 8, 78076-78085.	0.8	3
522	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. Journal of Clinical Oncology, 2013, 31, 4044-4044.	0.8	3

#	ARTICLE	IF	CITATIONS
523	Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabine and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study. <i>Gastroenterology</i> , 2011, 140, S-204.	0.6	2
524	Use of olaparib in patients with advanced gastric cancer –“ Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e76.	5.1	2
525	Adjuvant Chemotherapy: An Option for Asian Patients Only?. <i>Recent Results in Cancer Research</i> , 2012, 196, 291-305.	1.8	2
526	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 269-269.	0.8	2
527	Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4135-TPS4135.	0.8	2
528	A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS173-TPS173.	0.8	2
529	Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. <i>Chinese Clinical Oncology</i> , 2019, 8, 27-27.	0.4	2
530	Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2001, 33, 469-473.	1.3	2
531	A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions. <i>Cancer Research and Treatment</i> , 2014, 46, 280-287.	1.3	2
532	Results of Breast Conserving Surgery and Subsequent Postoperative Radiotherapy for Cases of Breast Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 142.	0.1	2
533	Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. <i>Anticancer Research</i> , 2014, 34, 6685-90.	0.5	2
534	Neoadjuvant Chemotherapy Followed by Radiotherapy in Epidermoid Carcinoma of Anus. <i>Tumori</i> , 2004, 90, 299-302.	0.6	1
535	Results of breast-conserving therapy for multifocal or multicentric breast cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 200-205.	0.7	1
536	Treatment for unresectable gastric cancer. <i>Journal of the Korean Medical Association</i> , 2015, 58, 209.	0.1	1
537	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1175-1182.	1.1	1
538	Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 158-162.	0.6	1
539	Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines. , 2000, 86, 632.		1
540	Antibodies that Inhibit Specific Cellular Pathways in Gastric Cancer. , 2017, , 101-113.		1

#	ARTICLE	IF	CITATIONS
541	Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells. , 2010, , .		1
542	Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD).. Journal of Clinical Oncology, 2013, 31, 11031-11031.	0.8	1
543	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2565-2565.	0.8	1
544	Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 351-351.	0.8	1
545	Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.. Journal of Clinical Oncology, 2015, 33, 4050-4050.	0.8	1
546	KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4138-TPS4138.	0.8	1
547	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. Journal of Clinical Oncology, 2018, 36, 4079-4079.	0.8	1
548	The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. Journal of Clinical Oncology, 2018, 36, 288-288.	0.8	1
549	Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2001, 33, 373-376.	1.3	1
550	Study of plasma TGF- β 1 level as a useful tumor marker in gastric cancer and prostate cancer. Immune Network, 2001, 1, 260.	1.6	1
551	Effect of Suboptimal Chemotherapy on Preoperative Chemoradiation in Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 78.	0.1	1
552	Myocardial Involvement of Carcinoid Heart Disease: A Case Report. Journal of the Korean Society of Echocardiography, 1998, 6, 95.	0.0	1
553	Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer.. Journal of Clinical Oncology, 2015, 33, 415-415.	0.8	1
554	A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2521-2521.	0.8	1
555	Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, 261-261.	0.8	1
556	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, 416-416.	0.8	1
557	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel \pm Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2022, 28, 3686-3694.	3.2	1
558	Phase 2 Trial of Gemcitabine Plus Uft in Oxaliplatin, Irinotecan and Fluoropyrimidine-Refractory Colorectal Cancer. Annals of Oncology, 2014, 25, v47.	0.6	0

#	ARTICLE	IF	CITATIONS
559	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016, 68, 750-755.	0.9	0
560	Adjuvant Treatment for Gastric Cancer. , 2019, , 353-357.		0
561	A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. <i>Clinical and Translational Science</i> , 2021, 14, 990-1001.	1.5	0
562	Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GE).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16078-e16078.	0.8	0
563	A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2001, 33, 225-228.	1.3	0
564	Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients. <i>Cancer Research and Treatment</i> , 2001, 33, 350-356.	1.3	0
565	Induction chemotherapy followed by radiotherapy in the treatment of anal cancer. <i>Oncology Reports</i> , 0, , .	1.2	0
566	The Role of Preoperative Chemotherapy in Patients with Inoperable Metastatic or Locally Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2004, 4, 7.	0.9	0
567	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. <i>The Korean Journal of Hematology</i> , 2005, 40, 192.	0.7	0
568	Abstract 3588: Antitumor activity of saracatinib, a c-Src/Abl kinase inhibitor, in gastric cancer. , 2011, , .		0
569	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 623-623.	0.8	0
570	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3624-3624.	0.8	0
571	A phase I/II study of oral paclitaxel in patients (pts) with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14572-e14572.	0.8	0
572	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4081-4081.	0.8	0
573	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 182-182.	0.8	0
574	Abstract 3442: Olaparib increases antitumor effects on epigenetically RAD51C-deficient human cancer cells.. , 2013, , .		0
575	Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13505-e13505.	0.8	0
576	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15066-e15066.	0.8	0

#	ARTICLE	IF	CITATIONS
577	Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.. Journal of Clinical Oncology, 2013, 31, LBA4001-LBA4001.	0.8	0
578	Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.. , 2013, , .		0
579	Real-world treatment patterns among patients with advanced gastric cancer in South Korea.. Journal of Clinical Oncology, 2014, 32, 152-152.	0.8	0
580	Metabolic landscape using 18F-FDG PET and its clinical significances in advanced biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, 252-252.	0.8	0
581	Acceptance of Foreign Clinical Data. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1994, 2, 91.	0.1	0
582	Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 4062-4062.	0.8	0
583	Metabolic landscape and prognostic value of HER2 in advanced gastric cancer.. Journal of Clinical Oncology, 2014, 32, 4061-4061.	0.8	0
584	Abstract 5479: Antitumor effect of KX-01, a novel Src and tubulin inhibitor, in triple negative breast cancer cells. Cancer Research, 2014, 74, 5479-5479.	0.4	0
585	Abstract 747: Evaluation of Src as a therapeutic target and development of biomarkers of Src inhibitor in cancer. , 2014, , .		0
586	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).. Journal of Clinical Oncology, 2015, 33, 133-133.	0.8	0
587	Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy.. Journal of Clinical Oncology, 2015, 33, 363-363.	0.8	0
588	Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 83-83.	0.8	0
589	Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy.. Journal of Clinical Oncology, 2015, 33, 11094-11094.	0.8	0
590	Abstract LB-107: Targeting ATR using a novel ATR inhibitor AZD6738 in human gastric cancer cells. , 2015, , .		0
591	Abstract LB-165: Antiproliferative effects of AZD6738 and the inhibition of DDR activity. , 2015, , .		0
592	Abstract 1714: The role and mechanism of JAB1 as a therapeutic target in biliary tract cancer. , 2015, , .		0
593	Abstract 3599: Resistance mechanisms to HER2-targeting treatment in HER2-positive gastric cancer. , 2015, , .		0
594	Abstract 2422: Pan-pim kinases inhibitor, AZD1208 suppresses tumor growth and synergistically interacts with an AKT inhibitor in gastric cancer cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
595	Effect of combined consideration of distinct signatures of VEGF and soluble VEGFR2 on prognostic implication in gastric cancer.. Journal of Clinical Oncology, 2016, 34, 56-56.	0.8	0
596	Prediction of metastatic pancreatic cancer patientsâ€™ survival using both host immunity and tumor metabolic activity.. Journal of Clinical Oncology, 2016, 34, 411-411.	0.8	0
597	Association of reduction of tumor metabolism with prognosis of advanced gastric cancer patients treated with palliative chemotherapy: Prospective cohort study.. Journal of Clinical Oncology, 2016, 34, 31-31.	0.8	0
598	Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.. Journal of Clinical Oncology, 2016, 34, 370-370.	0.8	0
599	Korean Cancer Patientsâ€™ Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067.	0.8	0
600	Abstract CT108: HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC). , 2016, , .		0
601	Abstract LB-107: Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells via modulation of DNA damage response. , 2016, , .		0
602	Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Anticancer Research, 2016, 36, 5455-5462.	0.5	0
603	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. Journal of Clinical Oncology, 2017, 35, 460-460.	0.8	0
604	Dynamics of soluble programmed death-ligand 1 (soluble PDL1) during chemotherapy and its prognostic implication in cancer patients.. Journal of Clinical Oncology, 2017, 35, 11542-11542.	0.8	0
605	Abstract 306: Antitumor effect of Wee1 inhibitor in gastric cancer cells. , 2017, , .		0
606	Abstract 5869: Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. , 2017, , .		0
607	Abstract 1421: Evaluation of DDR-targeting strategy using ATR inhibitor in biliary tract cancer. , 2017, , .		0
608	Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 306-306.	0.8	0
609	A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.. Journal of Clinical Oncology, 2018, 36, TPS3114-TPS3114.	0.8	0
610	The prognostic role of soluble transforming growth factor-Î² (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. Journal of Clinical Oncology, 2019, 37, 257-257.	0.8	0
611	Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.. Journal of Clinical Oncology, 2019, 37, 311-311.	0.8	0
612	404â€¦ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). , 2020, , .		0